# MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

> **NCT00089076** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Adult Grade III Lymphomatoid Granulomatosis
- B-cell Chronic Lymphocytic Leukemia
- Cutaneous B-cell Non-Hodgkin Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Intraocular Lymphoma
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Refractory Hairy Cell Leukemia
- Small Intestine Lymphoma
- Splenic Marginal Zone Lymphoma
- Testicular Lymphoma
- Waldenström Macroglobulinemia

## Interventions

- **BIOLOGICAL:** ipilimumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00089076
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** 2008-07
- **Final completion:** 2009-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089076, "MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00089076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*